View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMynaric 将来の成長Future 基準チェック /06現在、 Mynaricの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Aerospace & Defense 収益成長27.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Jan 04Mynaric AG Updates Earnings Guidance for the Full Year 2024Mynaric AG updated earnings guidance for the full year 2024. For the year, the company anticipates IFRS-15 revenue of EUR 14.1 million compared to previous guidance of a range estimating between EUR 16.0 million to EUR 24.0 million. The guidance decrease reflects shipments of CONDOR Mk3 terminals, originally expected to ship in late 2024, to slip into early 2025, due to shortages of key components from suppliers. These delays resulted in approximately EUR 2.6 million of revenue for terminals previously expected to ship in 2024 now expected to ship and revenue recognized in early 2025. Operating loss: the previous Company guidance of a range of operating loss estimating to range between a loss of EUR 55.0 million to EUR 50.0 million is unchanged.Price Target Changed • Jul 30Price target decreased by 29% to €31.50Down from €44.50, the current price target is an average from 2 analysts. New target price is 109% above last closing price of €15.05. Stock is down 28% over the past year. The company is forecast to post a net loss per share of €7.52 next year compared to a net loss per share of €15.48 last year.お知らせ • Jun 21Mynaric Provides Earnings Guidance for the Full Year 2024Mynaric provided earnings guidance for the full year 2024. For the fiscal year 2024, revenue outlook is driven by shipments of CONDOR Mk3 units to multiple customers. This outlook assumes it is able to ramp to its current production plans. This outlook remains at the lower end of the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately €65 million). The company expects its operating loss for the fiscal year 2024 to decrease significantly from last year's level due to higher revenue levels. This outlook remains in-line with the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately -€36 million). The outlook is based on the current projected production ramp and current liquidity projection. Should Mynaric experience either a pushout in its production schedule, fail to secure new orders as planned or incur delays in securing new orders from customers, there is a high likelihood the company could need to raise additional capital. Mynaric is also considering pursuing multiple alternative options in order to secure its cash needs and bolster its long-term success.お知らせ • Nov 12Mynaric Provides Earnings Guidance for the Full Year 2023Mynaric provides earnings guidance for the full year 2023. The company now expects full-year 2023 IFRS-15 revenue to remain around the same level as 2022 revenue of EUR 4.4 million compared to previous guidance of a significant increase. The guidance decrease is due to the production delay of CONDOR Mk3 that was previously scheduled to start in fourth quarter 2023. The company now expects full-year 2023 operating loss to be around the same level as last year compared to previous guidance of a moderate decrease relative to the EUR 73.8 million operating loss reported for full-year 2022.Price Target Changed • Sep 16Price target increased by 28% to €47.00Up from €36.67, the current price target is an average from 3 analysts. New target price is 172% above last closing price of €17.30. Stock is down 33% over the past year. The company is forecast to post a net loss per share of €10.21 next year compared to a net loss per share of €13.57 last year.Price Target Changed • Sep 07Price target decreased by 21% to €36.67Down from €46.67, the current price target is an average from 3 analysts. New target price is 110% above last closing price of €17.50. Stock is down 37% over the past year. The company is forecast to post a net loss per share of €9.28 next year compared to a net loss per share of €13.57 last year.すべての更新を表示Recent updatesお知らせ • Jun 12Nasdaq to Delist ADS of Mynaric AGThe Nasdaq Stock Market announced that it will delist the American Depository Shares of Mynaric AG. Mynaric’s security was suspended on February 18, 2025 and has not traded on Nasdaq since that time.お知らせ • May 01Mynaric AG announced delayed 20-F filingOn 04/30/2025, Mynaric AG announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • Mar 30Mynaric AG Announces Resignation of Bulent Altan as Chairman and Member of Supervisory Board Effective April 1, 2025Mynaric AG announced that Bulent Altan, on March 28, 2025, has tendered his resignation as Chairman and Member of the Supervisory Board of the Company for personal reasons effective April 1, 2025. Bulent Altan was elected Chairman of the Supervisory Board of the Company following his election as member of the Supervisory Board by the General Assembly in August 2023. The Supervisory Board of the Company will conduct a new election for the role of Chairman without undue delay. A new member will be appointed in due course in accordance with the provisions of applicable stock corporation act (Aktiengesetz).お知らせ • Mar 13Rocket Lab USA, Inc. (NasdaqCM:RKLB) entered into a non-binding term sheet to acquire Mynaric AG (XTRA:M0YN) from Lenders for $150 million.Rocket Lab USA, Inc. (NasdaqCM:RKLB) entered into a non-binding term sheet to acquire Mynaric AG (XTRA:M0YN) from Lenders for $150 million on March 10, 2025. As part of the acquisition, Rocket Lab would acquire 100% of the outstanding equity interests of Mynaric and initial purchase price is expected to be $75 million payable in either cash or shares of common stock of Rocket Lab, at Rocket Lab’s option, with the potential for additional earn-out consideration based on future revenue targets of the Mynaric business of up to an additional $75 million in shares of Rocket Lab common stock or cash, at Rocket Lab’s option. The initial closing purchase price will also be increased (and the potential earnout consideration correspondingly decreased) to the extent of any additional cash investment by the Lenders or their affiliates in Mynaric after completion of the StaRUG Restructuring and before the closing of the potential acquisition. If Rocket Lab USA, Inc chooses to issue cash consideration, then the proceeds from the offering will be used to fund the acquisition. The transaction is subject to receipt of certain governmental approvals, following the completion of Mynaric’s previously announced and pending StaRUG restructuring proceedings under German law, the completion of which would result in certain outstanding debt held by the Lenders converting into 100% of the equity of Mynaric, subject to customary due diligence and signing of definitive agreement.お知らせ • Mar 12Mynaric Updates on Operational Continuity and Ongoing Production and DeliveriesMynaric announced that it is continuing to ramp up production and customer deliveries of the CONDOR Mk3 optical communications terminal and updates on the background to the company’s StaRUG proceedings. The StaRUG proceedings, once completed, would provide for significant debt relief, enabling the company to continue to serve its current and potential customers, suppliers and partners. Focus on Delivering on Existing Contracts and Winning Future Opportunities: Mynaric is also continuing to pursue opportunities that explore the use of free-space optical communications for additional space programs. In addition to contributing to the U.S. Space Development Agency’s (SDA) Proliferated Warfighter Space Architecture (PWSA) Tranche 1 and Tranche 2 programs, Mynaric has also been recognized as a key development partner in multiple projects to develop quantum communication capabilities. Establishing a Stable Financial and Operational Footing Moving Forward: Mynaric’s lenders agreed to the restructuring concept on the condition that Mynaric initiates StaRUG proceedings and that the restructuring plan provides for a capital reduction to zero. To enable Mynaric to cover its expected ongoing operational and working capital until the conclusion of the StaRUG proceedings, Mynaric’s lenders committed a fourth bridge loan of USD 28 million in February 2025 as well as an additional USD 25 million restructuring loan, giving Mynaric the necessary resources to support its production plan and ongoing operations. The implementation of the financial restructuring through the StaRUG proceedings would safeguard jobs, protect creditor interests, and significantly reduce Mynaric’s cash interest burden.お知らせ • Feb 18+ 1 more updateMynaric AG(NasdaqGS:MYNA) dropped from NASDAQ Composite IndexMynaric AG has been dropped from the NASDAQ Composite Index.お知らせ • Feb 14Mynaric Announces Receipt of Delisting Notice from NasdaqMynaric announced that it received a delisting notification dated February 10, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market Inc. As previously disclosed, on February 7, 2025, Mynaric's management board, with the approval of its supervisory board, resolved on a financial restructuring by proceedings under the German Corporate Stabilization and Restructuring Act (Gesetz über den Stabilisierungs- und Restrukturierungsrahmen für Unternehmen) and notified the competent Munich Local Court - Restructuring Court - of such restructuring project (the "StaRUG Proceeding").On February 10, 2025, Mynaric received the Delisting Notice from Nasdaq notifying Mynaric that, as a result of the StaRUG Proceeding and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that Mynaric's American Depositary Shares representing its ordinary shares (the "ADS") will be delisted from Nasdaq. The Delisting Notice also advises Mynaric of its right to appeal Nasdaq's determination pursuant to procedures set in the Nasdaq Listing Rule 5800 Series. Mynaric does not intend to pursue an appeal. Trading of the ADS will be suspended at the opening of business on February 18, 2025. Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the ADS from listing and registration on Nasdaq. Nasdaq has previously notified Mynaric that it is no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) for failing to maintain a minimum market value of $50 million in listed securities, (ii) Nasdaq Listing Rule 5250(c)(2) for not filing an interim balance sheet and income statement as of and for the end of its second quarter on Form 6-K within six months following the end of Mynaric's second quarter, (iii) Nasdaq Listing Rule 5620(a) for failing to hold an annual meeting of shareholders within twelve months after the end of the Mynaric's fiscal year, and (iv) Nasdaq Listing Rule 5450(a)(1) for not meeting the minimum closing bid price of $1.00 per share of the ADS.お知らせ • Jan 16Mynaric AG, Annual General Meeting, Feb 21, 2025Mynaric AG, Annual General Meeting, Feb 21, 2025, at 10:00 W. Europe Standard Time.お知らせ • Jan 04Mynaric AG Updates Earnings Guidance for the Full Year 2024Mynaric AG updated earnings guidance for the full year 2024. For the year, the company anticipates IFRS-15 revenue of EUR 14.1 million compared to previous guidance of a range estimating between EUR 16.0 million to EUR 24.0 million. The guidance decrease reflects shipments of CONDOR Mk3 terminals, originally expected to ship in late 2024, to slip into early 2025, due to shortages of key components from suppliers. These delays resulted in approximately EUR 2.6 million of revenue for terminals previously expected to ship in 2024 now expected to ship and revenue recognized in early 2025. Operating loss: the previous Company guidance of a range of operating loss estimating to range between a loss of EUR 55.0 million to EUR 50.0 million is unchanged.お知らせ • Nov 05Mynaric AG, Annual General Meeting, Dec 11, 2024Mynaric AG, Annual General Meeting, Dec 11, 2024, at 10:00 W. Europe Standard Time.お知らせ • Nov 01Bronstein, Gewirtz & Grossman, LLC Announces Class Action Lawsuit Files Against Mynaric AGBronstein, Gewirtz & Grossman, LLC announced that a class action lawsuit has been filed against Mynaric AG (Mynaric) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Mynaric securities between June 20, 2024, and October 7, 2024, inclusive (Class Period). The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) lower-than-expected production yields and component supplier shortages of key components were causing production delays for Mynaric's CONDOR Mk3 product; (2) the foregoing issues were likely to have a material negative impact on the Company's revenue growth and cause the Company to incur an operating loss; (3) as a result, Mynaric was unlikely to meet its own previously issued financial guidance for fiscal year 2024; (4) accordingly, the Company's business and/or financial prospects were overstated; and (5) as a result, the Company's public statements were materially false and misleading at all relevant times.お知らせ • Oct 08Mynaric Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed SecuritiesMynaric AG announced that it received a notification letter dated October 2, 2024 (the ‘Deficiency Letter’) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (the ‘Nasdaq’) notifying that Mynaric is no longer in compliance with the Nasdaq continued listing criteria, including the Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum of $50 million in market value of listed securities (the ‘MVLS Requirement’). Nasdaq also determined that Mynaric does not meet the alternatives of total assets and total revenue for continued listing. The Deficiency Letter has no immediate effect on the listing of Mynaric’s American Depositary Shares representing its ordinary shares (the ‘ADS’), which continue to trade under the symbol ‘MYNA.’ The Deficiency Letter provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), Mynaric has a period of 180 calendar days from the date of the Deficiency Letter, or until March 31, 2025, to regain compliance with the MVLS Requirement. During this period, the ADS will continue to trade on Nasdaq. Nasdaq will deem Mynaric to have regained compliance with the MVLS Requirement if at any time during this compliance period Mynaric’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days. In the event Mynaric does not regain compliance with the MVLS Requirement by March 31, 2025, Mynaric will receive written notification from Nasdaq that Mynaric’s ADS are subject to delisting. At that time, Mynaric may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance, if Mynaric does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. In such event, Mynaric may also seek to apply for a transfer to The Nasdaq Capital Market if it meets the requirements for continued listing thereon. Mynaric is reviewing its options for regaining compliance with the MVLS Requirement and for remedying other future potential non-compliances with Nasdaq continued listing requirements. There can be no assurance that Mynaric will be able to regain compliance with the MVLS Requirement or other Nasdaq continued listing requirements in a timely fashion, in which case its securities would be delisted from Nasdaq.お知らせ • Sep 17Mynaric Advances Production of CONDOR Mk3Mynaric announced the successful advancement of the company's volume production ramp for the CONDOR Mk3. Mynaric continues to work through previously announced production delays and has realized near-term improvement in production yields and supply chain-related bottlenecks. Production delays of CONDOR Mk3 were caused by lower than expected production yields and supplier shortages of key components. Current shipments of the CONDOR Mk3 free space optical communications system will be part of the United States Space Development Agency (SDA) Tranche 1 program. Mynaric was selected by Northrop Grumman as the sole supplier of optical communications terminals for the SDA's Tranche 1 Transport and Tracking Layer programs and by York Space Systems for the SDA's Tranche 1 Transport Layer. Mynaric was also selected by Loft Federal to supply the CONDOR Mk3 terminals to NExT – the SDA's Experimental Testbed. In addition, Mynaric continues to pursue opportunities that explore the use of free-space optical communications for additional space programs. Mynaric has been recognized as a key development partner in Phase 2 of DARPA's Space-BACN program, was selected by the European Space Agency (ESA) to investigate optical technologies for next generation high-throughput optical inter-satellite links and was selected by the German government for multiple projects to develop quantum communication capabilities. In addition, Mynaric continues to diligently pursue additional capital sources to secure on-going operations and production ramp.New Risk • Sep 04New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€34m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€34m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-€49m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€46m net loss in 2 years). Market cap is less than US$100m (€19.6m market cap, or US$21.7m).New Risk • Aug 30New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €94m Forecast net loss in 2 years: €46m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-€49m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€34m). Currently unprofitable and not forecast to become profitable over next 2 years (€46m net loss in 2 years). Market cap is less than US$100m (€21.7m market cap, or US$24.1m).お知らせ • Aug 27+ 1 more updateMynaric AG Announces Management ChangesThe board of Mynaric AG announced the appointment of Andreas Reif with immediate effect as member of the management board and Chief Restructuring Officer. In his role as CRO, Andreas Reif will be integral to reducing costs and near-term cash consumption while working closely with customers to meet their requirements. Prior to joining Mynaric, Andreas Reif served in executive financial and operational roles and as a key advisor forindustrial manufacturing companies throughout Germany. Mynaric announced that the supervisory board and the chief executive officer, Mustafa Veziroglu, jointly decided on the termination of the office of Mustafa Veziroglu as CEO and member of the management board of Mynaric with immediate effect.New Risk • Aug 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-€49m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€34m). Market cap is less than US$100m (€44.1m market cap, or US$49.1m).お知らせ • Aug 20+ 1 more updateMynaric Announces Departure of Stefan Berndt Von-Bülow as CFOMynaric announced the voluntary departure of CFO Stefan Berndt von-Bülow for personal reasons, effective last week. Berndt von-Bülow has been with Mynaric since 2018 and assumed the role as CFO in 2020. As CFO, Berndt von-Bülow made significant contributions to the company's financial strategy and operations, investor relations, several capital raises, significant debt financing, and, particularly Mynaric's listing on Nasdaq in November 2021, during a time of significant growth and transformation. Mynaric has initiated a global search for a new CFO. In the interim, the two remaining members of the management team, Mustafa Veziroglu and Joachim Horwath, will assume the responsibilities of the CFO.Price Target Changed • Jul 30Price target decreased by 29% to €31.50Down from €44.50, the current price target is an average from 2 analysts. New target price is 109% above last closing price of €15.05. Stock is down 28% over the past year. The company is forecast to post a net loss per share of €7.52 next year compared to a net loss per share of €15.48 last year.お知らせ • Jul 23Mynaric AG, Annual General Meeting, Aug 29, 2024Mynaric AG, Annual General Meeting, Aug 29, 2024, at 10:00 W. Europe Standard Time.お知らせ • Jun 21Mynaric Provides Earnings Guidance for the Full Year 2024Mynaric provided earnings guidance for the full year 2024. For the fiscal year 2024, revenue outlook is driven by shipments of CONDOR Mk3 units to multiple customers. This outlook assumes it is able to ramp to its current production plans. This outlook remains at the lower end of the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately €65 million). The company expects its operating loss for the fiscal year 2024 to decrease significantly from last year's level due to higher revenue levels. This outlook remains in-line with the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately -€36 million). The outlook is based on the current projected production ramp and current liquidity projection. Should Mynaric experience either a pushout in its production schedule, fail to secure new orders as planned or incur delays in securing new orders from customers, there is a high likelihood the company could need to raise additional capital. Mynaric is also considering pursuing multiple alternative options in order to secure its cash needs and bolster its long-term success.お知らせ • Jun 14Mynaric AG to Report Fiscal Year 2023 Results on Jun 20, 2024Mynaric AG announced that they will report fiscal year 2023 results on Jun 20, 2024お知らせ • May 01Mynaric AG announced delayed 20-F filingOn 04/30/2024, Mynaric AG announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • Nov 12Mynaric Provides Earnings Guidance for the Full Year 2023Mynaric provides earnings guidance for the full year 2023. The company now expects full-year 2023 IFRS-15 revenue to remain around the same level as 2022 revenue of EUR 4.4 million compared to previous guidance of a significant increase. The guidance decrease is due to the production delay of CONDOR Mk3 that was previously scheduled to start in fourth quarter 2023. The company now expects full-year 2023 operating loss to be around the same level as last year compared to previous guidance of a moderate decrease relative to the EUR 73.8 million operating loss reported for full-year 2022.New Risk • Nov 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10.0% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€25m net loss in 2 years). Shareholders have been diluted in the past year (10% increase in shares outstanding).New Risk • Oct 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €90.1m (US$94.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€25m net loss in 2 years). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€90.1m market cap, or US$94.9m).Reported Earnings • Sep 17First half 2023 earnings released: €5.55 loss per share (vs €6.28 loss in 1H 2022)First half 2023 results: €5.55 loss per share (improved from €6.28 loss in 1H 2022). Net loss: €32.4m (loss narrowed 1.4% from 1H 2022). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Aerospace & Defense industry in Germany. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.Price Target Changed • Sep 16Price target increased by 28% to €47.00Up from €36.67, the current price target is an average from 3 analysts. New target price is 172% above last closing price of €17.30. Stock is down 33% over the past year. The company is forecast to post a net loss per share of €10.21 next year compared to a net loss per share of €13.57 last year.New Risk • Sep 15New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €73m Forecast net loss in 2 years: €21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€21m net loss in 2 years). Shareholders have been diluted in the past year (10% increase in shares outstanding).お知らせ • Sep 08Mynaric AG to Report First Half, 2023 Results on Sep 14, 2023Mynaric AG announced that they will report first half, 2023 results on Sep 14, 2023Price Target Changed • Sep 07Price target decreased by 21% to €36.67Down from €46.67, the current price target is an average from 3 analysts. New target price is 110% above last closing price of €17.50. Stock is down 37% over the past year. The company is forecast to post a net loss per share of €9.28 next year compared to a net loss per share of €13.57 last year.お知らせ • Aug 09Mynaric Announces Executive ChangesMynaric announced key results of the company's annual general assembly held on August 7, 2023. Following shareholder approval, industry veterans Bulent Altan and Margaret Abernathy joined Mynaric's Supervisory Board after receiving the requisite number of votes during the annual general assembly. They join the three re-elected Supervisory Board members: Dr. Hans Königsmann, Dr. Manfred Krischke, and Peter Müller-Brühl, effective immediately. Following the company's annual general assembly meeting, the Supervisory Board met and elected Bulent Altan as Chairman. Mustafa Veziroglu will serve as the company's Chief Executive Officer. Veziroglu will lead Mynaric's day-to-day business operations and strategy to produce laser communications terminals at scale for applications in space, air and terrestrial applications.お知らせ • Jul 01Mynaric AG, Annual General Meeting, Aug 07, 2023Mynaric AG, Annual General Meeting, Aug 07, 2023, at 10:00 Central European Standard Time. Location: Haus der Bayrischen Wirtschaft, Max-Joseph-Strasse 5, 80333 Munich, Germany Munich Germany Agenda: To consider Annual Financial Statement as of December 31, 2022; to consider Curriculum vitae of the candidates proposed for election to the Supervisory Board; and to consider other business matters.お知らせ • May 12+ 1 more updateMynaric Ag Announces Resignation of Mr. Altan as A Member of the Management BoardMynaric AG announced that Mr. Altan will resign from his position as member of the Management Board of Mynaric AG as of the end of the Annual General Meeting 2023 of the Company at the beginning of Third Quarter 2023.Price Target Changed • May 03Price target decreased by 13% to €51.17Down from €59.00, the current price target is an average from 3 analysts. New target price is 107% above last closing price of €24.70. Stock is down 31% over the past year. The company is forecast to post earnings per share of €2.94 next year compared to a net loss per share of €13.57 last year.Breakeven Date Change • May 01The 4 analysts covering Mynaric previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 22% per year to 2024. The company is expected to make a profit of €10.9m in 2025. Average annual earnings growth of 44% is required to achieve expected profit on schedule.お知らせ • Feb 01+ 1 more updateMynaric AG Appoints Mustafa Veziroglu as Co-CEO, Effective February 1, 2023Mynaric, AG announced the appointment of Mustafa Veziroglu as Co-CEO of the company, effective February 1, 2023. Mustafa Veziroglu joined Mynaric in August 2022 as President and since then has been responsible for all operational product-related activities within Mynaric overseeing the entire product lifecycle from development through delivery. With Mynaric's recent success in winning additional new customers and hitting important customer milestones, his role as Co-CEO will be to strengthen Mynaric's focus on 2023 execution targets and jointly lead the company with Co-CEO Bulent Altan.Breakeven Date Change • Nov 18Forecast to breakeven in 2023The 3 analysts covering Mynaric expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €12.0m in 2023. Average annual earnings growth of 50% is required to achieve expected profit on schedule.Breakeven Date Change • Jul 29Forecast breakeven date moved forward to 2023The 3 analysts covering Mynaric previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of €12.0m in 2023. Average annual earnings growth of 80% is required to achieve expected profit on schedule.Reported Earnings • May 01Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: €10.68 loss per share (down from €5.90 loss in FY 2020). Net loss: €45.4m (loss widened 130% from FY 2020). Revenue missed analyst estimates by 79%. Earnings per share (EPS) also missed analyst estimates by 117%. Over the next year, revenue is forecast to grow 1,547%, compared to a 22% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.Reported Earnings • Oct 24First half 2021 earnings released: €3.94 loss per share (vs €2.33 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses increased. First half 2021 results: Revenue: €1.35m (up €1.26m from 1H 2020). Net loss: €16.1m (loss widened 120% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Mar 09New 90-day low: €63.20The company is down 4.0% from its price of €65.60 on 08 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Aerospace & Defense industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €167 per share.Is New 90 Day High Low • Feb 06New 90-day high: €84.00The company is up 50% from its price of €56.00 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Aerospace & Defense industry, which is up 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €184 per share.Is New 90 Day High Low • Jan 07New 90-day high: €75.40The company is up 5.0% from its price of €72.00 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Aerospace & Defense industry, which is up 29% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €174 per share.Is New 90 Day High Low • Nov 07New 90-day low: €56.00The company is down 14% from its price of €65.40 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Aerospace & Defense industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €383 per share.Reported Earnings • Sep 23First half earnings releasedOver the last 12 months the company has reported total losses of €11.9m, with losses widening by 50% from the prior year. Total revenue was €9.80m over the last 12 months, up 185% from the prior year. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Mynaric は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:M0YN - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20235-94-34-29N/A9/30/20236-83-40-35N/A6/30/20237-73-46-40N/A3/31/20236-74-54-45N/A12/31/20224-74-62-50N/A9/30/20222-68-60-49N/A6/30/20220-62-59-47N/A3/31/20221-54-55-43N/A12/31/20212-45-50-39N/A9/30/2021-1-37-46-33N/A6/30/202114-29-42-27N/A3/31/202112-25-37-22N/A12/31/20201-20-32-17N/A9/30/20201-17-27-14N/A6/30/20204-13-23-12N/A3/31/20205-12-19-10N/A12/31/20190-10-15-8N/A9/30/20194-9N/AN/AN/A6/30/20193-8N/AN/AN/A3/31/20194-8N/AN/AN/A12/31/20185-8-13-8N/A9/30/20185-10N/AN/AN/A6/30/20185-9N/AN/AN/A3/31/20184-8N/AN/AN/A12/31/20173-7N/AN/AN/A9/30/20172-3N/AN/AN/A6/30/20171-2N/AN/AN/A3/31/20171-2N/AN/AN/A12/31/20161-2N/A-2N/A12/31/20152-1N/A-1N/A12/31/201410N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: M0YNの予測収益成長が 貯蓄率 ( 1.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: M0YNの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: M0YNの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: M0YNの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: M0YNの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: M0YNの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YCapital-goods 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/19 16:55終値2025/07/31 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Mynaric AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Austin MoellerCanaccord GenuityZafer RüzgarPareto SecuritiesJuergen WagnerStifel, Equities Research
お知らせ • Jan 04Mynaric AG Updates Earnings Guidance for the Full Year 2024Mynaric AG updated earnings guidance for the full year 2024. For the year, the company anticipates IFRS-15 revenue of EUR 14.1 million compared to previous guidance of a range estimating between EUR 16.0 million to EUR 24.0 million. The guidance decrease reflects shipments of CONDOR Mk3 terminals, originally expected to ship in late 2024, to slip into early 2025, due to shortages of key components from suppliers. These delays resulted in approximately EUR 2.6 million of revenue for terminals previously expected to ship in 2024 now expected to ship and revenue recognized in early 2025. Operating loss: the previous Company guidance of a range of operating loss estimating to range between a loss of EUR 55.0 million to EUR 50.0 million is unchanged.
Price Target Changed • Jul 30Price target decreased by 29% to €31.50Down from €44.50, the current price target is an average from 2 analysts. New target price is 109% above last closing price of €15.05. Stock is down 28% over the past year. The company is forecast to post a net loss per share of €7.52 next year compared to a net loss per share of €15.48 last year.
お知らせ • Jun 21Mynaric Provides Earnings Guidance for the Full Year 2024Mynaric provided earnings guidance for the full year 2024. For the fiscal year 2024, revenue outlook is driven by shipments of CONDOR Mk3 units to multiple customers. This outlook assumes it is able to ramp to its current production plans. This outlook remains at the lower end of the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately €65 million). The company expects its operating loss for the fiscal year 2024 to decrease significantly from last year's level due to higher revenue levels. This outlook remains in-line with the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately -€36 million). The outlook is based on the current projected production ramp and current liquidity projection. Should Mynaric experience either a pushout in its production schedule, fail to secure new orders as planned or incur delays in securing new orders from customers, there is a high likelihood the company could need to raise additional capital. Mynaric is also considering pursuing multiple alternative options in order to secure its cash needs and bolster its long-term success.
お知らせ • Nov 12Mynaric Provides Earnings Guidance for the Full Year 2023Mynaric provides earnings guidance for the full year 2023. The company now expects full-year 2023 IFRS-15 revenue to remain around the same level as 2022 revenue of EUR 4.4 million compared to previous guidance of a significant increase. The guidance decrease is due to the production delay of CONDOR Mk3 that was previously scheduled to start in fourth quarter 2023. The company now expects full-year 2023 operating loss to be around the same level as last year compared to previous guidance of a moderate decrease relative to the EUR 73.8 million operating loss reported for full-year 2022.
Price Target Changed • Sep 16Price target increased by 28% to €47.00Up from €36.67, the current price target is an average from 3 analysts. New target price is 172% above last closing price of €17.30. Stock is down 33% over the past year. The company is forecast to post a net loss per share of €10.21 next year compared to a net loss per share of €13.57 last year.
Price Target Changed • Sep 07Price target decreased by 21% to €36.67Down from €46.67, the current price target is an average from 3 analysts. New target price is 110% above last closing price of €17.50. Stock is down 37% over the past year. The company is forecast to post a net loss per share of €9.28 next year compared to a net loss per share of €13.57 last year.
お知らせ • Jun 12Nasdaq to Delist ADS of Mynaric AGThe Nasdaq Stock Market announced that it will delist the American Depository Shares of Mynaric AG. Mynaric’s security was suspended on February 18, 2025 and has not traded on Nasdaq since that time.
お知らせ • May 01Mynaric AG announced delayed 20-F filingOn 04/30/2025, Mynaric AG announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Mar 30Mynaric AG Announces Resignation of Bulent Altan as Chairman and Member of Supervisory Board Effective April 1, 2025Mynaric AG announced that Bulent Altan, on March 28, 2025, has tendered his resignation as Chairman and Member of the Supervisory Board of the Company for personal reasons effective April 1, 2025. Bulent Altan was elected Chairman of the Supervisory Board of the Company following his election as member of the Supervisory Board by the General Assembly in August 2023. The Supervisory Board of the Company will conduct a new election for the role of Chairman without undue delay. A new member will be appointed in due course in accordance with the provisions of applicable stock corporation act (Aktiengesetz).
お知らせ • Mar 13Rocket Lab USA, Inc. (NasdaqCM:RKLB) entered into a non-binding term sheet to acquire Mynaric AG (XTRA:M0YN) from Lenders for $150 million.Rocket Lab USA, Inc. (NasdaqCM:RKLB) entered into a non-binding term sheet to acquire Mynaric AG (XTRA:M0YN) from Lenders for $150 million on March 10, 2025. As part of the acquisition, Rocket Lab would acquire 100% of the outstanding equity interests of Mynaric and initial purchase price is expected to be $75 million payable in either cash or shares of common stock of Rocket Lab, at Rocket Lab’s option, with the potential for additional earn-out consideration based on future revenue targets of the Mynaric business of up to an additional $75 million in shares of Rocket Lab common stock or cash, at Rocket Lab’s option. The initial closing purchase price will also be increased (and the potential earnout consideration correspondingly decreased) to the extent of any additional cash investment by the Lenders or their affiliates in Mynaric after completion of the StaRUG Restructuring and before the closing of the potential acquisition. If Rocket Lab USA, Inc chooses to issue cash consideration, then the proceeds from the offering will be used to fund the acquisition. The transaction is subject to receipt of certain governmental approvals, following the completion of Mynaric’s previously announced and pending StaRUG restructuring proceedings under German law, the completion of which would result in certain outstanding debt held by the Lenders converting into 100% of the equity of Mynaric, subject to customary due diligence and signing of definitive agreement.
お知らせ • Mar 12Mynaric Updates on Operational Continuity and Ongoing Production and DeliveriesMynaric announced that it is continuing to ramp up production and customer deliveries of the CONDOR Mk3 optical communications terminal and updates on the background to the company’s StaRUG proceedings. The StaRUG proceedings, once completed, would provide for significant debt relief, enabling the company to continue to serve its current and potential customers, suppliers and partners. Focus on Delivering on Existing Contracts and Winning Future Opportunities: Mynaric is also continuing to pursue opportunities that explore the use of free-space optical communications for additional space programs. In addition to contributing to the U.S. Space Development Agency’s (SDA) Proliferated Warfighter Space Architecture (PWSA) Tranche 1 and Tranche 2 programs, Mynaric has also been recognized as a key development partner in multiple projects to develop quantum communication capabilities. Establishing a Stable Financial and Operational Footing Moving Forward: Mynaric’s lenders agreed to the restructuring concept on the condition that Mynaric initiates StaRUG proceedings and that the restructuring plan provides for a capital reduction to zero. To enable Mynaric to cover its expected ongoing operational and working capital until the conclusion of the StaRUG proceedings, Mynaric’s lenders committed a fourth bridge loan of USD 28 million in February 2025 as well as an additional USD 25 million restructuring loan, giving Mynaric the necessary resources to support its production plan and ongoing operations. The implementation of the financial restructuring through the StaRUG proceedings would safeguard jobs, protect creditor interests, and significantly reduce Mynaric’s cash interest burden.
お知らせ • Feb 18+ 1 more updateMynaric AG(NasdaqGS:MYNA) dropped from NASDAQ Composite IndexMynaric AG has been dropped from the NASDAQ Composite Index.
お知らせ • Feb 14Mynaric Announces Receipt of Delisting Notice from NasdaqMynaric announced that it received a delisting notification dated February 10, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market Inc. As previously disclosed, on February 7, 2025, Mynaric's management board, with the approval of its supervisory board, resolved on a financial restructuring by proceedings under the German Corporate Stabilization and Restructuring Act (Gesetz über den Stabilisierungs- und Restrukturierungsrahmen für Unternehmen) and notified the competent Munich Local Court - Restructuring Court - of such restructuring project (the "StaRUG Proceeding").On February 10, 2025, Mynaric received the Delisting Notice from Nasdaq notifying Mynaric that, as a result of the StaRUG Proceeding and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that Mynaric's American Depositary Shares representing its ordinary shares (the "ADS") will be delisted from Nasdaq. The Delisting Notice also advises Mynaric of its right to appeal Nasdaq's determination pursuant to procedures set in the Nasdaq Listing Rule 5800 Series. Mynaric does not intend to pursue an appeal. Trading of the ADS will be suspended at the opening of business on February 18, 2025. Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the ADS from listing and registration on Nasdaq. Nasdaq has previously notified Mynaric that it is no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) for failing to maintain a minimum market value of $50 million in listed securities, (ii) Nasdaq Listing Rule 5250(c)(2) for not filing an interim balance sheet and income statement as of and for the end of its second quarter on Form 6-K within six months following the end of Mynaric's second quarter, (iii) Nasdaq Listing Rule 5620(a) for failing to hold an annual meeting of shareholders within twelve months after the end of the Mynaric's fiscal year, and (iv) Nasdaq Listing Rule 5450(a)(1) for not meeting the minimum closing bid price of $1.00 per share of the ADS.
お知らせ • Jan 16Mynaric AG, Annual General Meeting, Feb 21, 2025Mynaric AG, Annual General Meeting, Feb 21, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Jan 04Mynaric AG Updates Earnings Guidance for the Full Year 2024Mynaric AG updated earnings guidance for the full year 2024. For the year, the company anticipates IFRS-15 revenue of EUR 14.1 million compared to previous guidance of a range estimating between EUR 16.0 million to EUR 24.0 million. The guidance decrease reflects shipments of CONDOR Mk3 terminals, originally expected to ship in late 2024, to slip into early 2025, due to shortages of key components from suppliers. These delays resulted in approximately EUR 2.6 million of revenue for terminals previously expected to ship in 2024 now expected to ship and revenue recognized in early 2025. Operating loss: the previous Company guidance of a range of operating loss estimating to range between a loss of EUR 55.0 million to EUR 50.0 million is unchanged.
お知らせ • Nov 05Mynaric AG, Annual General Meeting, Dec 11, 2024Mynaric AG, Annual General Meeting, Dec 11, 2024, at 10:00 W. Europe Standard Time.
お知らせ • Nov 01Bronstein, Gewirtz & Grossman, LLC Announces Class Action Lawsuit Files Against Mynaric AGBronstein, Gewirtz & Grossman, LLC announced that a class action lawsuit has been filed against Mynaric AG (Mynaric) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Mynaric securities between June 20, 2024, and October 7, 2024, inclusive (Class Period). The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) lower-than-expected production yields and component supplier shortages of key components were causing production delays for Mynaric's CONDOR Mk3 product; (2) the foregoing issues were likely to have a material negative impact on the Company's revenue growth and cause the Company to incur an operating loss; (3) as a result, Mynaric was unlikely to meet its own previously issued financial guidance for fiscal year 2024; (4) accordingly, the Company's business and/or financial prospects were overstated; and (5) as a result, the Company's public statements were materially false and misleading at all relevant times.
お知らせ • Oct 08Mynaric Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed SecuritiesMynaric AG announced that it received a notification letter dated October 2, 2024 (the ‘Deficiency Letter’) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (the ‘Nasdaq’) notifying that Mynaric is no longer in compliance with the Nasdaq continued listing criteria, including the Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum of $50 million in market value of listed securities (the ‘MVLS Requirement’). Nasdaq also determined that Mynaric does not meet the alternatives of total assets and total revenue for continued listing. The Deficiency Letter has no immediate effect on the listing of Mynaric’s American Depositary Shares representing its ordinary shares (the ‘ADS’), which continue to trade under the symbol ‘MYNA.’ The Deficiency Letter provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), Mynaric has a period of 180 calendar days from the date of the Deficiency Letter, or until March 31, 2025, to regain compliance with the MVLS Requirement. During this period, the ADS will continue to trade on Nasdaq. Nasdaq will deem Mynaric to have regained compliance with the MVLS Requirement if at any time during this compliance period Mynaric’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days. In the event Mynaric does not regain compliance with the MVLS Requirement by March 31, 2025, Mynaric will receive written notification from Nasdaq that Mynaric’s ADS are subject to delisting. At that time, Mynaric may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance, if Mynaric does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. In such event, Mynaric may also seek to apply for a transfer to The Nasdaq Capital Market if it meets the requirements for continued listing thereon. Mynaric is reviewing its options for regaining compliance with the MVLS Requirement and for remedying other future potential non-compliances with Nasdaq continued listing requirements. There can be no assurance that Mynaric will be able to regain compliance with the MVLS Requirement or other Nasdaq continued listing requirements in a timely fashion, in which case its securities would be delisted from Nasdaq.
お知らせ • Sep 17Mynaric Advances Production of CONDOR Mk3Mynaric announced the successful advancement of the company's volume production ramp for the CONDOR Mk3. Mynaric continues to work through previously announced production delays and has realized near-term improvement in production yields and supply chain-related bottlenecks. Production delays of CONDOR Mk3 were caused by lower than expected production yields and supplier shortages of key components. Current shipments of the CONDOR Mk3 free space optical communications system will be part of the United States Space Development Agency (SDA) Tranche 1 program. Mynaric was selected by Northrop Grumman as the sole supplier of optical communications terminals for the SDA's Tranche 1 Transport and Tracking Layer programs and by York Space Systems for the SDA's Tranche 1 Transport Layer. Mynaric was also selected by Loft Federal to supply the CONDOR Mk3 terminals to NExT – the SDA's Experimental Testbed. In addition, Mynaric continues to pursue opportunities that explore the use of free-space optical communications for additional space programs. Mynaric has been recognized as a key development partner in Phase 2 of DARPA's Space-BACN program, was selected by the European Space Agency (ESA) to investigate optical technologies for next generation high-throughput optical inter-satellite links and was selected by the German government for multiple projects to develop quantum communication capabilities. In addition, Mynaric continues to diligently pursue additional capital sources to secure on-going operations and production ramp.
New Risk • Sep 04New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€34m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€34m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-€49m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€46m net loss in 2 years). Market cap is less than US$100m (€19.6m market cap, or US$21.7m).
New Risk • Aug 30New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €94m Forecast net loss in 2 years: €46m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-€49m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€34m). Currently unprofitable and not forecast to become profitable over next 2 years (€46m net loss in 2 years). Market cap is less than US$100m (€21.7m market cap, or US$24.1m).
お知らせ • Aug 27+ 1 more updateMynaric AG Announces Management ChangesThe board of Mynaric AG announced the appointment of Andreas Reif with immediate effect as member of the management board and Chief Restructuring Officer. In his role as CRO, Andreas Reif will be integral to reducing costs and near-term cash consumption while working closely with customers to meet their requirements. Prior to joining Mynaric, Andreas Reif served in executive financial and operational roles and as a key advisor forindustrial manufacturing companies throughout Germany. Mynaric announced that the supervisory board and the chief executive officer, Mustafa Veziroglu, jointly decided on the termination of the office of Mustafa Veziroglu as CEO and member of the management board of Mynaric with immediate effect.
New Risk • Aug 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-€49m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€34m). Market cap is less than US$100m (€44.1m market cap, or US$49.1m).
お知らせ • Aug 20+ 1 more updateMynaric Announces Departure of Stefan Berndt Von-Bülow as CFOMynaric announced the voluntary departure of CFO Stefan Berndt von-Bülow for personal reasons, effective last week. Berndt von-Bülow has been with Mynaric since 2018 and assumed the role as CFO in 2020. As CFO, Berndt von-Bülow made significant contributions to the company's financial strategy and operations, investor relations, several capital raises, significant debt financing, and, particularly Mynaric's listing on Nasdaq in November 2021, during a time of significant growth and transformation. Mynaric has initiated a global search for a new CFO. In the interim, the two remaining members of the management team, Mustafa Veziroglu and Joachim Horwath, will assume the responsibilities of the CFO.
Price Target Changed • Jul 30Price target decreased by 29% to €31.50Down from €44.50, the current price target is an average from 2 analysts. New target price is 109% above last closing price of €15.05. Stock is down 28% over the past year. The company is forecast to post a net loss per share of €7.52 next year compared to a net loss per share of €15.48 last year.
お知らせ • Jul 23Mynaric AG, Annual General Meeting, Aug 29, 2024Mynaric AG, Annual General Meeting, Aug 29, 2024, at 10:00 W. Europe Standard Time.
お知らせ • Jun 21Mynaric Provides Earnings Guidance for the Full Year 2024Mynaric provided earnings guidance for the full year 2024. For the fiscal year 2024, revenue outlook is driven by shipments of CONDOR Mk3 units to multiple customers. This outlook assumes it is able to ramp to its current production plans. This outlook remains at the lower end of the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately €65 million). The company expects its operating loss for the fiscal year 2024 to decrease significantly from last year's level due to higher revenue levels. This outlook remains in-line with the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately -€36 million). The outlook is based on the current projected production ramp and current liquidity projection. Should Mynaric experience either a pushout in its production schedule, fail to secure new orders as planned or incur delays in securing new orders from customers, there is a high likelihood the company could need to raise additional capital. Mynaric is also considering pursuing multiple alternative options in order to secure its cash needs and bolster its long-term success.
お知らせ • Jun 14Mynaric AG to Report Fiscal Year 2023 Results on Jun 20, 2024Mynaric AG announced that they will report fiscal year 2023 results on Jun 20, 2024
お知らせ • May 01Mynaric AG announced delayed 20-F filingOn 04/30/2024, Mynaric AG announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Nov 12Mynaric Provides Earnings Guidance for the Full Year 2023Mynaric provides earnings guidance for the full year 2023. The company now expects full-year 2023 IFRS-15 revenue to remain around the same level as 2022 revenue of EUR 4.4 million compared to previous guidance of a significant increase. The guidance decrease is due to the production delay of CONDOR Mk3 that was previously scheduled to start in fourth quarter 2023. The company now expects full-year 2023 operating loss to be around the same level as last year compared to previous guidance of a moderate decrease relative to the EUR 73.8 million operating loss reported for full-year 2022.
New Risk • Nov 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10.0% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€25m net loss in 2 years). Shareholders have been diluted in the past year (10% increase in shares outstanding).
New Risk • Oct 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €90.1m (US$94.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€25m net loss in 2 years). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€90.1m market cap, or US$94.9m).
Reported Earnings • Sep 17First half 2023 earnings released: €5.55 loss per share (vs €6.28 loss in 1H 2022)First half 2023 results: €5.55 loss per share (improved from €6.28 loss in 1H 2022). Net loss: €32.4m (loss narrowed 1.4% from 1H 2022). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Aerospace & Defense industry in Germany. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.
Price Target Changed • Sep 16Price target increased by 28% to €47.00Up from €36.67, the current price target is an average from 3 analysts. New target price is 172% above last closing price of €17.30. Stock is down 33% over the past year. The company is forecast to post a net loss per share of €10.21 next year compared to a net loss per share of €13.57 last year.
New Risk • Sep 15New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €73m Forecast net loss in 2 years: €21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€21m net loss in 2 years). Shareholders have been diluted in the past year (10% increase in shares outstanding).
お知らせ • Sep 08Mynaric AG to Report First Half, 2023 Results on Sep 14, 2023Mynaric AG announced that they will report first half, 2023 results on Sep 14, 2023
Price Target Changed • Sep 07Price target decreased by 21% to €36.67Down from €46.67, the current price target is an average from 3 analysts. New target price is 110% above last closing price of €17.50. Stock is down 37% over the past year. The company is forecast to post a net loss per share of €9.28 next year compared to a net loss per share of €13.57 last year.
お知らせ • Aug 09Mynaric Announces Executive ChangesMynaric announced key results of the company's annual general assembly held on August 7, 2023. Following shareholder approval, industry veterans Bulent Altan and Margaret Abernathy joined Mynaric's Supervisory Board after receiving the requisite number of votes during the annual general assembly. They join the three re-elected Supervisory Board members: Dr. Hans Königsmann, Dr. Manfred Krischke, and Peter Müller-Brühl, effective immediately. Following the company's annual general assembly meeting, the Supervisory Board met and elected Bulent Altan as Chairman. Mustafa Veziroglu will serve as the company's Chief Executive Officer. Veziroglu will lead Mynaric's day-to-day business operations and strategy to produce laser communications terminals at scale for applications in space, air and terrestrial applications.
お知らせ • Jul 01Mynaric AG, Annual General Meeting, Aug 07, 2023Mynaric AG, Annual General Meeting, Aug 07, 2023, at 10:00 Central European Standard Time. Location: Haus der Bayrischen Wirtschaft, Max-Joseph-Strasse 5, 80333 Munich, Germany Munich Germany Agenda: To consider Annual Financial Statement as of December 31, 2022; to consider Curriculum vitae of the candidates proposed for election to the Supervisory Board; and to consider other business matters.
お知らせ • May 12+ 1 more updateMynaric Ag Announces Resignation of Mr. Altan as A Member of the Management BoardMynaric AG announced that Mr. Altan will resign from his position as member of the Management Board of Mynaric AG as of the end of the Annual General Meeting 2023 of the Company at the beginning of Third Quarter 2023.
Price Target Changed • May 03Price target decreased by 13% to €51.17Down from €59.00, the current price target is an average from 3 analysts. New target price is 107% above last closing price of €24.70. Stock is down 31% over the past year. The company is forecast to post earnings per share of €2.94 next year compared to a net loss per share of €13.57 last year.
Breakeven Date Change • May 01The 4 analysts covering Mynaric previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 22% per year to 2024. The company is expected to make a profit of €10.9m in 2025. Average annual earnings growth of 44% is required to achieve expected profit on schedule.
お知らせ • Feb 01+ 1 more updateMynaric AG Appoints Mustafa Veziroglu as Co-CEO, Effective February 1, 2023Mynaric, AG announced the appointment of Mustafa Veziroglu as Co-CEO of the company, effective February 1, 2023. Mustafa Veziroglu joined Mynaric in August 2022 as President and since then has been responsible for all operational product-related activities within Mynaric overseeing the entire product lifecycle from development through delivery. With Mynaric's recent success in winning additional new customers and hitting important customer milestones, his role as Co-CEO will be to strengthen Mynaric's focus on 2023 execution targets and jointly lead the company with Co-CEO Bulent Altan.
Breakeven Date Change • Nov 18Forecast to breakeven in 2023The 3 analysts covering Mynaric expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €12.0m in 2023. Average annual earnings growth of 50% is required to achieve expected profit on schedule.
Breakeven Date Change • Jul 29Forecast breakeven date moved forward to 2023The 3 analysts covering Mynaric previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of €12.0m in 2023. Average annual earnings growth of 80% is required to achieve expected profit on schedule.
Reported Earnings • May 01Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: €10.68 loss per share (down from €5.90 loss in FY 2020). Net loss: €45.4m (loss widened 130% from FY 2020). Revenue missed analyst estimates by 79%. Earnings per share (EPS) also missed analyst estimates by 117%. Over the next year, revenue is forecast to grow 1,547%, compared to a 22% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
Reported Earnings • Oct 24First half 2021 earnings released: €3.94 loss per share (vs €2.33 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses increased. First half 2021 results: Revenue: €1.35m (up €1.26m from 1H 2020). Net loss: €16.1m (loss widened 120% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Mar 09New 90-day low: €63.20The company is down 4.0% from its price of €65.60 on 08 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Aerospace & Defense industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €167 per share.
Is New 90 Day High Low • Feb 06New 90-day high: €84.00The company is up 50% from its price of €56.00 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Aerospace & Defense industry, which is up 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €184 per share.
Is New 90 Day High Low • Jan 07New 90-day high: €75.40The company is up 5.0% from its price of €72.00 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Aerospace & Defense industry, which is up 29% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €174 per share.
Is New 90 Day High Low • Nov 07New 90-day low: €56.00The company is down 14% from its price of €65.40 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Aerospace & Defense industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €383 per share.
Reported Earnings • Sep 23First half earnings releasedOver the last 12 months the company has reported total losses of €11.9m, with losses widening by 50% from the prior year. Total revenue was €9.80m over the last 12 months, up 185% from the prior year.